5/18/2023 0 Comments Horizon therapeuticsNachrichten zu HORIZON THERAPEUTICS PLC Zeitĭavidson Kempner Capital Management LP: Form 8.3 - Horizon Therapeutics plcįorm 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plcĭJ Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc If a connected EFM, state nature of connection (Note 10) If a connected EFM, name of offeree/offeror with which connected Is a Supplemental Form 8 attached? (Note 9) YES/NO Date of disclosure (d) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction (Note 8)Īgreements, arrangements or understandings relating to options or derivativesįull details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. Option money paid/received per unit (Note 5) Number of securities to which the option relates (Note 7) Writing, selling, purchasing, varying etc. (i) Writing, selling, purchasing or varying Product name, e.g. (c) Options transactions in respect of existing relevant securities (b) Derivatives transactions (other than options transactions) Product name, e.g. (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: (3) Options and agreements to purchase/sell (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) KEY INFORMATION Name of person dealing (Note 1)Ĭlass of relevant security to which the dealings being disclosed relate (Note 2)c Sign up for the Daily Brief, Silicon Republic’s digest of essential sci-tech news.1. “Amgen is aligned with that commitment and passion and will continue to maximise the value of the current portfolio and pipeline and accelerate the ability to reach more patients globally.”ġ0 things you need to know direct to your inbox every weekday. “These accomplishments are all rooted in our employees’ deep commitment, dedication and personal passion for those impacted by rare, autoimmune and severe inflammatory diseases,” Walbert added. Horizon president, chair and CEO Tim Walbert said the team has built “one of the fastest growing and most respected companies” in the biotechnology industry. In 2021, it also purchased a manufacturing facility in Waterford from EirGen Pharma to support the growth of its on-market rare disease medicines and pipeline biologics. In May, the biotech shared plans to hire 100 new staff over an 18-month period as it opened its new global headquarters in Dublin. Horizon has more than 2,000 employees worldwide, with hundreds employed in Ireland across a variety of key functions including finance, legal and technical operations. “Additionally, the potential new medicines in Horizon’s pipeline strongly complement our own R&D portfolio.”įounded in 2008, Horizon established its global headquarters in Dublin in 2014 following the combination of the businesses Horizon Pharma and Vidara Therapeutics International. “Amgen’s decades of leadership in inflammation and nephrology, combined with our global presence and world-class biologics capabilities, will enable us to reach many more patients with first-in-class medicines like Tepezza, Krystexxa and Uplizna,” Bradway said. ![]() The acquisition will add several approved drugs into Amgen’s portfolio, including the thyroid eye disease treatment Tepezza.Īmgen CEO and chair Robert A Bradway said the acquisition is in line with its long-term growth strategy of providing innovative medicines that address the needs of “patients who suffer from serious diseases”. Horizon’s share price surged in recent weeks after the company revealed it was in talks with three pharma giants – including Amgen – about a potential takeover. The deal values Horizon at $27.8bn on a fully diluted basis and implies an enterprise value of roughly $28.3bn. The deal will see Amgen pay $116.50 in cash for each Horizon share, which is a premium of nearly 20pc on Horizon’s closing price of $97.29 per share on 9 December. The acquisition will add several approved drugs into Amgen’s portfolio, along with potential new medicines from Horizon’s R&D pipeline.Īmgen has agreed to buy Dublin-headquartered biotech company Horizon Therapeutics for $27.8bn in its biggest acquisition to date.
0 Comments
Leave a Reply. |